Though cancer cachexia has been researched extensively, it remains challenging to understand and treat. Though cancer cachexia has been researched extensively, it remains challenging to understand and ...

Cachexia is a process that accompanies many chronic diseases, and consists of a combination of wasting of lean body mass, increased energy expenditure, and a paradoxical loss of appetite. Cachexia ...

The dietary supplement melatonin does not improve the symptoms of cachexia in patients with advanced cancer, according to a study published online February 25 in the Journal of Clinical Oncology.

Cachexia, defined as a loss of body weight, fat, and muscle mass that occurs in patients with chronic diseases, including cancer, remains a notable clinical challenge. With limited viable treatment ...

Cancer cachexia is a multifactorial syndrome marked by a severe loss of body weight due primarily to the wasting of skeletal muscle and adipose tissue. This syndrome is often accompanied by systemic ...

A new model of cancer-related cachexia promises to help scientists understand why patients with cancer show severe wasting, which in turn may drive the development of better therapies. Cachexia refers ...

Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitisExpanded pipeline strategy ...

Understanding the importance of using the right diagnostic criteria for cachexia is crucial, as it can significantly influence the health and survival of cancer patients. Maintaining good health and ...

A study published in Cell Reports Aug. 6 describes the generation of a new mouse model developed at Hollings Cancer Center that could lead to a better understanding of the cachexia syndrome. This ...

The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cancer cachexia therapeutics market and it is poised to grow by USD 568.85 million during 2019-2023, progressing at a CAGR of 6% during the ...